Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia

Best Practice & Research. Clinical Haematology
Rong Chen, William Plunkett

Abstract

Chronic lymphocytic leukaemia (CLL) is characterised by the dependence on the overexpression of anti-apoptotic proteins to maintain their survival. Based on this biological context, a strategy for CLL therapy was proposed using inhibitors of transcription and translation to transiently reduce the short-lived survival proteins and induce cell death. This includes inhibitors of the cyclin-dependent kinases required for the activation of RNA polymerase II, as well as homoharringtonine and silvestrol, the natural compounds that inhibit translation. As their actions are independent of p53 or ataxia telangiectasia mutated (ATM) function, agents that act by such mechanisms are promising to overcome resistance to current CLL therapy. Further, the combination of inhibitors of transcription and translation, together with other approaches that interfere with the function of anti-apoptotic proteins, may initiate synergistic killing in CLL.

References

Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·C DaniP Jeanteur
Jun 15, 1994·Biochemical and Biophysical Research Communications·M D LosiewiczP J Worland
Nov 1, 1995·Trends in Biochemical Sciences·C Y Chen, A B Shyu
Jul 1, 1996·Molecular and Cellular Biology·K Y YankulovD L Bentley
Sep 1, 1996·British Journal of Haematology·D GottardiF Caligaris-Cappio
Jun 29, 1999·Cold Spring Harbor Symposia on Quantitative Biology·J PengD H Price
Jul 25, 2000·The Journal of Biological Chemistry·S H ChaoD H Price
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianS O'Brien
Nov 28, 2000·Expert Opinion on Investigational Drugs·L R Kelland
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Apr 3, 2001·Nature Reviews. Molecular Cell Biology·C J WiluszS W Peltz
Apr 20, 2001·Critical Reviews in Oncology/hematology·H H Sedlacek
Dec 18, 2001·Cancer·H M KantarjianS M O'Brien
Jun 4, 2002·Nature Reviews. Molecular Cell Biology·Guy S Salvesen, Colin S Duckett
Jul 6, 2002·Science·I Bernard Weinstein
Nov 15, 2002·International Journal of Cancer. Journal International Du Cancer·Steven J McClueDavid P Lane
May 15, 2003·The Journal of Biological Chemistry·David A SolomonErik S Knudsen
May 4, 2004·Nature Medicine·Guo-Jun ZhangWilliam G Kaelin
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Apr 27, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K LacrimaF Bertoni
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Florence I RaynaudPaul Workman
Apr 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Geoffrey I Shapiro
Aug 4, 2006·Molecular Cell·B Matija Peterlin, David H Price
Aug 5, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·G SiemeisterKlaus Bosslet
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael F X GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Feb 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan O'BrienKanti R Rai
Mar 17, 2007·Molecular Cancer Therapeutics·Kalpana S JoshiSomesh Sharma

❮ Previous
Next ❯

Citations

Apr 27, 2013·Leukemia Research·Cinzia ScavulloGiorgio Lambertenghi Deliliers
Jun 23, 2015·International Journal of Cancer. Journal International Du Cancer·Daniela OpelSimone Fulda
Nov 2, 2012·Cancer Biology & Therapy·Małgorzata RogalińskaZofia M Kiliańska
Jan 13, 2015·International Journal of Oncology·Małgorzata RogalińskaZofia M Kiliańska
Jan 13, 2015·Blood·Tadeusz Robak, Piotr Smolewski
Jul 14, 2011·British Journal of Cancer·C SpagnuoloG L Russo
Mar 3, 2011·Nature Reviews. Clinical Oncology·Sarah P Blagden, Anne E Willis
Apr 30, 2017·Oncology Letters·Małgorzata RogalińskaZofia M Kilianska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cell Cycle Control & Proteolysis

Key regulators of cell cycle, including cyclins, cyclin dependent kinase inhibitors, DNA replication factors, are controlled by proteolysis. Discover the latest research on cell cycle control and proteolysis.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.